{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:19Z","timestamp":1790790559681,"version":"4.1.0"},"reference-count":32,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1179\/joc.2007.19.3.322","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T13:05:52Z","timestamp":1389272752000},"page":"322-331","source":"Crossref","is-referenced-by-count":4,"title":["Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study"],"prefix":"10.1080","volume":"19","author":[{"given":"C.","family":"Kosmas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gassiamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Skopelitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Karabelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"CIT0001","first-page":"17","volume":"1999","author":"Salminen E","journal-title":"J Clin Oncol"},{"key":"CIT0002","first-page":"1413","volume":"17","author":"Nabholtz JM","year":"1999","journal-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol"},{"key":"CIT0003","first-page":"35","volume":"1999","author":"Sjostrom J","journal-title":"Eur J Cancer"},{"key":"CIT0004","unstructured":"Monnier A, Bonneterre J, Roche H, et al. Phase III study: Taxotere (TXT) versus 5-Fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy. Ann Oncol 1998; 9 (Suppl 4): 12 (abstr 580)."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"Chan S","year":"1999","journal-title":"The 303 Study Group. J Clin Oncol"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","volume":"18","author":"Paridaens R","year":"2000","journal-title":"J Clin Oncol"},{"key":"CIT0007","unstructured":"Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxoru-bicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 1997; 16: la (abstr 2)."},{"key":"CIT0008","first-page":"861","volume":"58","author":"Ahmann DI","year":"1974","journal-title":"Cancer Chemother Rep"},{"key":"CIT0009","first-page":"185","volume":"1","author":"Bitran JD","year":"1995","journal-title":"Clin Cancer Res"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<561::AID-CNCR19>3.0.CO;2-#"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.1996.14.11.2993","volume":"11","author":"Leone BA","year":"1996","journal-title":"J Clin Oncol"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.24"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-3-429"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"CIT0017","unstructured":"Reed E, Kohn EC, Sarosy G, et al. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 1995; 22 (Suppl. 6): 90-6."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.341"},{"key":"CIT0019","first-page":"25","volume":"6","author":"Liebmann JE","year":"1994","journal-title":"Oncol Res"},{"key":"CIT0020","unstructured":"Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmaco-kinetics and pharmacodynamics. Semin Oncol 1995; 22 (Suppl. 6): 16-23."},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0919"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<774::AID-CNCR9>3.0.CO;2-5"},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2001.19.1.119","volume":"19","author":"Kosmas C","year":"2001","journal-title":"J Clin Oncol"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10162"},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.1996.14.3.783","volume":"14","author":"Kennedy MJ","year":"1996","journal-title":"J Clin Oncol"},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.1996.14.1.95","volume":"14","author":"Tolcher AW","year":"1996","journal-title":"J Clin Oncol"},{"key":"CIT0027","first-page":"655","volume":"8","author":"Pagani","year":"1997","journal-title":"Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200008000-00010"},{"key":"CIT0029","first-page":"1087","volume":"10","author":"Cerny T","year":"1999","journal-title":"Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol"},{"key":"CIT0030","unstructured":"Lorusso V, Crucitta E, Sambiasi D, Attolico M, De Lena M. Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: a phase II study. Ann Oncol 2000; 11 (Suppl 4): 36 (abstract 154)."},{"key":"CIT0031","first-page":"2879","volume":"13","author":"Ravdin PM","year":"1995","journal-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracene-dione-resistant breast cancer. J Clin Oncol"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","volume":"13","author":"Valero V","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10256018808623883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:48:57Z","timestamp":1565052537000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2007.19.3.322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,7,18]]},"published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1179\/joc.2007.19.3.322"],"URL":"https:\/\/doi.org\/10.1179\/joc.2007.19.3.322","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}